This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 51.5 kDa. As a result of glycosylation, the protein migrates as 66-86 kDa under reducing (R) condition, and 120-140 kDa under non-reducing (NR) condition (SDS-PAGE).
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human B7-2, Fc Tag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Loaded Human B7-2, Fc Tag (Cat. No. CD6-H5257) on Protein A Biosensor, can bind Human / Cynomolgus / Rhesus macaque CD28, His Tag (Cat. No. CD8-H52Hc) with an affinity constant of 4.5 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Human B7-2, Fc Tag (Cat. No. CD6-H5257) on Protein A Biosensor, can bind Human CTLA-4, His Tag, active dimer (Cat. No. CT4-H52H9) with an affinity constant of 1.03 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Flow Cytometry assay shows that recombinant Human B7-2, Fc Tag (Cat.No. CD6-H5257) can bind to CD28 expressed on Jurkat E6.1. The concentration of B7-2 used is 2 μg/ml (Routinely tested).
FACS analysis shows that the binding of Human B7-2, Fc Tag to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing anti-CD28 antibody. The concentration of B7-2 used is 2 μg/ml. The IC50 is 0.022 μg/ml (Routinely tested).
FACS assay shows that Human B7-2, Fc Tag (Cat. No. CD6-H5257) can bind to 293T cells overexpressing human CTLA4 protein. The concentration of Human B7-2 is 3 μg/ml (Routinely tested).
Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma
Authors: Grzegorz B. Gmyrek, et al.
Journal: Cell Immunol 2017
Application: Binding assays
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $340.00
Price(USD) : $1440.00
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.